SKP2 and breast cancer: Taken together, these observations suggest that SKP2’s oncogenic activity is mediated through ERα and plays a vital role in estrogen signaling in hormone-driven (i.e. luminal) BC and may explain why our signature, based on the control of SKP2 protein levels, is less correlated with clinical outcome in the ER− subtypes.